Literature DB >> 29960901

Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey.

José Ignacio Fortea1, Ángela Puente2, Iranzu Ezcurra3, Antonio Cuadrado2, María Teresa Arias-Loste2, Joaquín Cabezas2, Susana Llerena2, Paula Iruzubieta2, Carlos Rodríguez-Lope2, Patricia Huelin2, Fernando Casafont2, Emilio Fábrega2, Javier Crespo2.   

Abstract

BACKGROUND: Knowledge of haematological abnormalities in cirrhosis has greatly improved in recent years. AIMS: To evaluate how Spanish Digestive Disease specialists manage haemostatic alterations and associated disorders in patients with cirrhosis.
METHODS: All members of the Spanish Association for the Study of the Liver and Spanish Society of Digestive Pathology were invited to fill in a web-based questionnaire.
RESULTS: 135 professionals, 93 hepatologists and 42 non-hepatologists responded to the survey. The concept of rebalanced haemostasis was known by 74.8% of them. Most specialists corrected the INR and thrombocytopenia before invasive procedures with moderate risk of bleeding or major surgery and in severe gastrointestinal bleeding. The threshold of platelets and, especially, INR used to administer blood products varied greatly. Pharmacological prophylaxis of venous thromboembolism prevailed, but it was highly dependent on the INR and platelet figures. Most participants initiated anticoagulation regardless of the degree of portal vein thrombosis, even in patients ineligible for transplantation. In potential candidates, only 56% maintained it indefinitely or until liver transplantation. No major differences between hepatologists and non-hepatologists were found.
CONCLUSIONS: A significant variability and certain deviation from current guidelines was observed among Spanish Digestive Disease specialists regarding management of haemostatic alterations and associated disorders in cirrhosis.
Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticoagulants; Haemorrhage; Haemostasis; Thrombosis

Mesh:

Substances:

Year:  2018        PMID: 29960901     DOI: 10.1016/j.dld.2018.06.003

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Rebalanced hemostasis in liver disease: a misunderstood coagulopathy.

Authors:  Lara N Roberts
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey.

Authors:  Nicoletta Riva; Marc Carrier; Alex Gatt; Walter Ageno
Journal:  Res Pract Thromb Haemost       Date:  2020-09-11

Review 3.  Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia.

Authors:  Domenico Alvaro; Nicola Caporaso; Edoardo Giovanni Giannini; Angelo Iacobellis; Mariacristina Morelli; Pierluigi Toniutto; Francesco Violi
Journal:  Eur J Clin Invest       Date:  2021-02-26       Impact factor: 4.686

4.  Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkers in Cirrhotic Patients With or Without Portal Venous Thrombosis.

Authors:  Wenhua Ren; Jing Zhang; Yuying Chen; Meng Wen; Yu Su; Yujing Zhao; Shan Lu; Jun Wu
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  Anticoagulation after transjugular intrahepatic portosystemic shunt for portal hypertension: A systematic review and meta analysis.

Authors:  Pan Jiao; Xu-Ying Chen; Hong-Yan Zheng; Jia Qin; Chao Li; Xiao-Lin Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.